Price Concessions By Manufacturers To Payers Rose Sharply In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
Net spending on all drugs rose 8.5% to $310bn in the US in 2015 when discounts, rebates and other price concessions are considered, annual IMS review says.
You may also be interested in...
US Branded Drug Invoice Price Increases Moderate In 2016
Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.
US Branded Drug Invoice Price Increases Moderate In 2016
Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.